2. Search Result
Search Result
Results for "

Pcsk9+Inhibitors

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

3

Peptides

2

Inhibitory Antibodies

1

Natural
Products

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148673
    Laroprovstat
    1 Publications Verification

    AZD0780; Pcsk9-IN-12

    		 PCSK9 Cardiovascular Disease Metabolic Disease
    Laroprovstat (AZD0780) is an orall active PCSK9 inhibitor. PCSK9-IN-12 has bind affinity for PCSK9 with a Kd value of <200 nM. Laroprovstat binds to a pocket in the PCSK9 C-terminal domain and does not affect the PCSK9-LDL receptor (LDLR) interaction. Laroprovstat inhibits lysosomal trafficking of PSCK9-LDLR complexes and prevents PCSK9-induced LDLR degradation. Laroprovstat can be used for the research of hypercholesterolemia .
    Laroprovstat
  • HY-P2276
    Pep2-8

    		PCSK9 Cancer
    Pep2-8 is a PCSK9 inhibitor with a binding KD of 0.7 μM and an IC50 of 1.4 μM .
    Pep2-8
  • HY-101832
    SBC-110736
    1 Publications Verification

    		 PCSK9 Cardiovascular Disease Metabolic Disease
    SBC-110736 is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor extracted from patent WO2014150395A1 .
    SBC-110736
  • HY-12402
    SBC-115076
    3 Publications Verification

    		 PCSK9 Cardiovascular Disease
    SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism .
    SBC-115076
  • HY-N2127
    Pinostrobin
    3 Publications Verification

    		 Amyloid-β Apoptosis Ser/Thr Protease HSV Interleukin Related Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Pinostrobin is a flavonoid with anti-cancer, antioxidant, antiviral and neuroprotective activities. Pinostrobin has oral activity. Pinostrobin is a potent PCSK9 inhibitor that inhibits the catalytic activity of PCSK9. Pinostrobin can be used in the research of viral infections, cancer, leukemia, cardiovascular and cerebrovascular diseases, cirrhosis, inflammation and neurological diseases .
    Pinostrobin
  • HY-P9928A
    Alirocumab (anti-PCSK9)
    1 Publications Verification

    REGN 727(anti-Pcsk9); SAR 236553(anti-Pcsk9)

    		 PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1 Cardiovascular Disease Cancer
    Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation [9] .
    Alirocumab (anti-PCSK9)
  • HY-152221
    PCSK9-IN-10

    		PCSK9 Cardiovascular Disease Metabolic Disease
    PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia .
    PCSK9-IN-10
  • HY-163794
    DC371739

    		ANGPTL PCSK9 Metabolic Disease
    DC371739 is a potent and orally activity PCSK9 inhibitor. DC371739 decreases the mRNA expression of PCSK9 and ANGPTL3. DC371739 decreases the protein expression of PCSK9 and increases the protein expression of LDLR. DC371739 has the potential for the research of hyperlipidemia .
    DC371739
  • HY-152223
    PCSK9-IN-11

    		PCSK9 Cardiovascular Disease
    PCSK9-IN-11 (compound 5r) is a potent and orally active PCSK9 inhibitor. PCSK9-IN-11 exhibits PCSK9 transcriptional inhibitory activity in HepG2 cells, with an IC50 of 5.7 μM. PCSK9-IN-11 increases LDL receptor (LDLR) protein level. PCSK9-IN-11 can be used for atherosclerosis research .
    PCSK9-IN-11
  • HY-P99816
    Ralpancizumab

    		PCSK9 Metabolic Disease
    Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke .
    Ralpancizumab
  • HY-141714
    SBC-115337

    		PCSK9 Cardiovascular Disease Cancer
    SBC-115337, as a potent benzofuran compound, is a PCSK9 inhibitor with an IC50 value of 0.5 μM .
    SBC-115337
  • HY-148758
    PCSK9-IN-13

    		PCSK9 Cardiovascular Disease Metabolic Disease
    PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC50 of 537 nM .
    PCSK9-IN-13
  • HY-120088
    PF-06446846
    Maximum Cited Publications
    6 Publications Verification

    		 PCSK9 Cardiovascular Disease
    PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 directly and selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region .
    PF-06446846
  • HY-157434
    PCSK9-IN-23

    		PCSK9 Cardiovascular Disease
    PCSK9-IN-23 (compound 5C) is a potent PCSK9 inhibitor. PCSK9-IN-23 blocks PCSK9 secretion from HepG2 cells, significantly increases LDL receptor (LDLR) expression .
    PCSK9-IN-23
  • HY-P11071
    PCSK9 Inhibitor, EGF-A

    		PCSK9 Cardiovascular Disease
    PCSK9 Inhibitor, EGF-A is a PCSK9 inhibitor. PCSK9 Inhibitor, EGF-A is residues 293-334 of the EGF-A domain of the low-density lipoprotein (LDL) receptor. PCSK9 Inhibitor, EGF-A can prevent PCSK9-induced intracellular LDLR degradation. PCSK9 Inhibitor, EGF-A can be used in the study of hypercholesterolemia and premature atherosclerosis .
    PCSK9 Inhibitor, EGF-A
  • HY-149310
    Dim16

    		PCSK9 HMG-CoA Reductase (HMGCR) Metabolic Disease
    Dim16 is a dual PCSK9 inhibitor and HMG-CoAR inhibitor, with an IC50 of 0.8 nM against human PCSK9 and an IC50 of 146.8 μM against HMG-CoAR. Dim16 disrupts the PCSK9-LDLR protein-protein interaction, inhibits the catalytic activity of HMG-CoAR, enhances cellular uptake of extracellular LDL, and suppresses PCSK9-induced platelet aggregation. Dim16 can be used in research related to hypercholesterolemia .
    Dim16
  • HY-134482
    PCSK9-IN-1

    		PCSK9 Cardiovascular Disease
    PCSK9-IN-1 is a novel and highly potent cyclic peptide PCSK9 inhibitor with a Ki value of 1.46 nM.
    PCSK9-IN-1
  • HY-179106
    PCSK9-IN-34

    		PCSK9 Cardiovascular Disease
    PCSK9-IN-34 is a small molecule PCSK9 inhibitor. PCSK9-IN-34 can be used for research on cardiovascular conditions .
    PCSK9-IN-34
  • HY-161434
    PCSK9-IN-26

    		PCSK9 Metabolic Disease
    PCSK9-IN-26 (Compound 116) is an PCSK9 inhibitor (IC50 < 1 nM). PCSK9-IN-26 can be used for metabolic research .
    PCSK9-IN-26
  • HY-161435
    PCSK9-IN-27

    		PCSK9 Metabolic Disease
    PCSK9-IN-27 (Compound 108) is a PCSK9 inhibitor (IC50: 3.4 nM). PCSK9-IN-27 reduces LDLR degradation and increases LDL-C uptake .
    PCSK9-IN-27
  • HY-161939
    7030B-C5

    		PCSK9 Cardiovascular Disease
    7030B-C5 is a PCSK9 inhibitor (IC50=1.61 μM). 7030B-C5 can significantly reduce plasma cholesterol and triglyceride (TG) levels in vivo and slow the progression of atherosclerosis. 7030B-C5 can be used in the study of cardiovascular diseases .
    7030B-C5
  • HY-153454
    PCSK9-IN-18

    		PCSK9 Metabolic Disease
    PCSK9-IN-18 (compound 188) is a potent PCSK9 inhibitor with a KD value of <200 nM .
    PCSK9-IN-18
  • HY-153391
    PCSK9-IN-14

    		PCSK9 Metabolic Disease
    PCSK9-IN-14 (compound Ia-8) is a potent PCSK9 inhibitor .
    PCSK9-IN-14
  • HY-148689
    SPC4061

    		PCSK9 Metabolic Disease
    SPC4061 an antisense nucleotide, is a potent PCSK9 inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases .
    SPC4061
  • HY-148689A
    SPC4061 sodium

    		PCSK9 Metabolic Disease
    SPC4061 an antisense nucleotide, sodium is a potent PCSK9 inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases .
    SPC4061 sodium
  • HY-161940
    PCSK9-IN-30

    		PCSK9 Cardiovascular Disease
    PCSK9-IN-30 (Compound 3f) is a PCSK9 inhibitor. PCSK9-IN-30 interacts with a cryptic binding groove of PCSK9, inhibiting the binding of PCSK9 to the low-density lipoprotein receptor (LDLR) (IC50 = 537 nM), restoring the uptake of low-density lipoprotein (LDL) by liver cells, and ultimately reducing plasma cholesterol levels. PCSK9-IN-30 exhibits good bioavailability in mice and can be used for research in the field of cardiovascular diseases .
    PCSK9-IN-30
  • HY-175189
    PCSK9-IN-33

    		PCSK9 Metabolic Disease
    PCSK9-IN-33 (Compound 1'f) is a PCSK9 inhibitor with an IC50 of 161 nM. PCSK9-IN-33 can be used for hypercholesterolemia research .
    PCSK9-IN-33
  • HY-153453
    PCSK9-IN-17

    		PCSK9 Cardiovascular Disease
    PCSK9-IN-17 is a PCSK9 inhibitor. PCSK9-IN-17 can be used for the research of cholesterol metabolism (WO2020150474A1, compound 105) .
    PCSK9-IN-17
  • HY-155006
    PCSK9-IN-19

    		PCSK9 Metabolic Disease
    PCSK9-IN-19 (Compound 1) is a PCSK9 inhibitor. PCSK9-IN-19 can be used for research of high LDL-cholesterol levels and prevention of coronary artery disease .
    PCSK9-IN-19
  • HY-153452
    PCSK9-IN-16

    		PCSK9 Cardiovascular Disease
    PCSK9-IN-16 is a potent PCSK9 inhibitor. PCSK9-IN-16 is extracted from patent WO2020150474, example 87, has the potential for hypercholesterolemia and other cardiovascular diseases research .
    PCSK9-IN-16
  • HY-155415
    PCSK9-IN-20

    		PCSK9 Cardiovascular Disease
    PCSK9-IN-20 (Compound 3i) is a PCSK9 inhibitor with an IC50 of 3.96 µM. PCSK9-IN-20 decreases PCSK9 and increases LDLR protein expression in vitro .
    PCSK9-IN-20
  • HY-161938
    BRD8518

    		PCSK9 LDLR Metabolic Disease
    BRD8518 is a PCSK9 inhibitor (EC50=0.23 μM). BRD8518 lowers blood lipids by upregulating LDLR expression and stimulating LDL uptake. BRD8518 can be used in the study of cardiovascular diseases .
    BRD8518
  • HY-161942
    PCSK9-IN-31

    		PCSK9 Metabolic Disease
    PCSK9-IN-31 (Compound WX002) is an orally active PCSK9 inhibitor. PCSK9-IN-31 can lower low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) in high cholesterol fed model rats .
    PCSK9-IN-31
  • HY-101832R
    SBC-110736 (Standard)

    		PCSK9 Reference Standards Cardiovascular Disease Metabolic Disease
    SBC-110736 (Standard) is the analytical standard of SBC-110736 (HY-101832). This product is intended for research and analytical applications. SBC-110736 is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor extracted from patent WO2014150395A1 .
    SBC-110736 (Standard)
  • HY-W1126955
    Enlicitide (decanoate)

    MK-0616 (decanoate)

    		 PCSK9 Metabolic Disease Inflammation/Immunology
    Enlicitide (MK-0616) decanoate is an orally active macrocyclic peptide PCSK9 inhibitor. Enlicitide decanoate binds to PCSK9, blocks its interaction with low-density lipoprotein receptor (LDLR), and enhances hepatic clearance of LDL-C. Enlicitide decanoate reduces atherogenic lipoproteins, including non-HDL cholesterol, apolipoprotein B, and lipoprotein (a). Enlicitide decanoate is applicable to research related to hypercholesterolemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease .
    Enlicitide (decanoate)
  • HY-149310A
    Dim16 hydrochloride

    		PCSK9 HMG-CoA Reductase (HMGCR) Metabolic Disease
    Dim16 hydrochloride is a dual PCSK9 inhibitor and HMG-CoAR inhibitor, with an IC50 of 0.8 nM against human PCSK9 and an IC50 of 146.8 μM against HMG-CoAR. Dim16 hydrochloride disrupts the PCSK9-LDLR protein-protein interaction, inhibits the catalytic activity of HMG-CoAR, enhances cellular uptake of extracellular LDL, and suppresses PCSK9-induced platelet aggregation. Dim16 hydrochloride can be used in research related to hypercholesterolemia .
    Dim16 hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: